You are here

Funding

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional) - Expiration Date: August 4, 2020
  • Participating Organization(s) and Components:  National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.
    Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
    This FOA is patterned on, but unrelated to, a series of FOAs for “Research Answers to NCI’s Provocative Questions".
  • Open Date: July 1, 2019
  • Amount of Award: NCI intends to commit $4,000,000 in FY 2021 to fund 6-8 awards.
  • Due Date: August 1, 2019; August 3, 2020, by 5:00 PM local time of applicant organization.
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-032.html
  • End Date: August 4, 2020
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional) - Expiration Date: November 13, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
  • Purpose: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
  • Open Date: October 12, 2019
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.
  • Due Date: November 12, 2019, November 12, 2020  by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-326.html
  • End Date: November 13, 2020
High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) - Expiration Date: January 8, 2021
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) - Expiration Date: April 30, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
  • Open Date: April 30, 2020
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date:

    Applications will be accepted on a rolling basis, beginning on 04/30/2020.

    All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • More Information: NIH
  • Expiration Date: April 30, 2021
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) - Expiration Date: April 30, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
  • Open Date: April 30, 2020
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year..
  • Due Date:

    Applications will be accepted on a rolling basis, beginning on 04/30/2020.

    All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • More Information: NIH
  • Expiration Date: April 30, 2021
NIAID New Innovator PAR for post-doctoral fellows - Expiration Date: October 14, 2021

As part of the NIAID commitment to increase opportunities for post-doctoral fellows, the NIAID New Innovator Award (DP2), PAR-19-296, was published last week. The purpose is to support post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research relevant to the mission of NIAID. Applicants approved for funding would have one year to secure an independent, tenure-track (or equivalent) faculty position at an U.S. extramural institution to activate the award.  Through this initiative, NIAID wants to encourage shorter post-doctoral fellowships and provide the opportunity for creative scientists with little to no preliminary data to start their independent careers earlier. NIAID intends to award up to 10 applications per year.
 
Please share this FOA with any talented non-independent postdocs (research and/or clinical doctorate degree, U.S. or non-U.S. citizens), as well as with investigators who may know of appropriate candidates. The next receipt date is November 4, 2019 (once per year); clinical trials are not allowed for this FOA. The DAIDS contact for this PAR is Diane Lawrence.  Her contact info is below:
 
Diane Lawrence, Ph.D.
Program Officer, Pathogenesis and Basic Research Branch
Basic Science Program, Division of AIDS, NIAID
5601 Fishers Lane, Rm 9G22
Bethesda, MD 20892
240-627-3202, lawrencedi@niaid.nih.gov

Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) - Expiration Date: September 8, 2022
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
  • Open Date: December 7, 2019
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date:Standard AIDS dates apply.
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: September 8, 2022